Flemming Winther Bach

Real-life efficacy of pregabalin for the treatment of peripheral neuropathic pain in daily clinical practice in Denmark: the NEP-TUNE study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Michael E Crawford, Copenhagen City Pain Clinic, Copenhagen K, Aalborg, Denmark.
  • ,
  • Peter Bo Poulsen, Pfizer Denmark ApS, Ballerup, Aalborg, Denmark.
  • ,
  • Berit Schiøttz-Christensen, Spine Center Southern Denmark, Lillebælt Hospital, Middelfart, Aalborg, Denmark.
  • ,
  • Andreas Habicht, Signifikans ApS, Vedbæk, Aalborg, Denmark.
  • ,
  • Mette Strand, Pfizer Denmark ApS, Ballerup, Aalborg, Denmark.
  • ,
  • Flemming W Bach
Objective: The aim of this study was to provide evidence regarding the real-life efficacy of pregabalin in the treatment of peripheral neuropathic pain (NeP) in Denmark.
Methods: In this prospective, observational, noninterventional study, pregabalin (Lyrica®) was prescribed following usual clinical practice. Compared with baseline, the primary study end points after 3 months of observation were changes in 1) the average level of pain during the past week, 2) the worst level of pain during the past week, and 3) the least level of pain during the past week. The Wilcoxon signed-rank test was used to perform paired analyses, and a multivariate regression analysis investigated factors driving change in pain.
Results: A total of 86 of the 128 patients included were regarded as efficacy evaluable (those completing 3 months of pregabalin treatment). Patients (59 years) were long-time sufferers of peripheral NeP, and 38% of them had comorbidities. The majority had previously been treated with tricyclic antidepressants or gabapentin. The average dose of pregabalin was 81.5 mg/d at baseline and 240 mg/d after 3 months. A clinically and statistically significant improvement of 2.2 points in the average level of pain intensity was found after 3 months. The higher the pain intensity at baseline, the higher was the reduction of the pain score. Positive results were also found for pain-related sleep interference, patients’ global impression of change, quality of life, and work and productivity impairment. Twenty-one patients reported 28 adverse events.
Conclusion: This real-life study indicates that for some patients (two-thirds), addition of pregabalin for peripheral NeP helps to reduce their pain intensity significantly.
OriginalsprogEngelsk
TidsskriftJournal of Pain Research
Vol/bind9
Sider (fra-til)293-302
Antal sider10
ISSN1178-7090
DOI
StatusUdgivet - maj 2016
Eksternt udgivetJa

Se relationer på Aarhus Universitet Citationsformater

ID: 107071669